CSPC Pharmaceutical Group’s SYS-6063 gained clinical trial clearance from China’s National Medical Products Administration for systemic lupus erythematosus. SYS-6063 is described as an mRNA-LNP-based dual-target CAR T-cell injection, designed to address relapsed or refractory SLE. The clearance expands CSPC’s footprint in immune-cell therapies and adds another mRNA-delivery CAR approach to a competitive field that is seeking alternatives to traditional ex vivo manufacturing. For developers and investors watching China’s regulatory pipeline, the decision signals continued acceleration of next-gen cell and gene approaches into autoimmune indications. Key next steps will include enrollment, safety characterization, and whether efficacy signals—especially in refractory SLE—emerge in early cohorts.